Depression and Anxiety Trial, Recruiting NCT07159061 Sponsor: University of Pennsylvania Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT07159061
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People of any gender are welcome to participate
  • Adults between 18 and 65 years of age
  • People who have been diagnosed with Major Depressive Disorder (MDD) — either as a standalone condition or as part of Bipolar II — confirmed using a standard clinical assessment tool
  • People whose depression scores at least 16 on a standard rating scale used to measure depression severity (confirm with trial site)
  • People with normal cognitive (thinking and memory) function
  • People who can read and understand English
  • People who are able to give their own informed consent to participate

Who may not be able to join:

  • Female participants who are pregnant
  • People outside the 18–65 age range
  • People with medical reasons that prevent an MRI scan, such as certain medical implants or severe claustrophobia
  • People who are currently taking any medications that affect mood or mental health (including antidepressants), or who are currently receiving any form of therapy
  • People with a neurological condition, a co-existing psychotic disorder, cognitive or developmental impairment, or active alcohol or drug use issues within the past 6 months — or any other condition that the lead researcher believes could affect brain scan results or overall suitability for the study
  • People who do not speak English
  • People with vision loss that cannot be corrected with glasses or contact lenses
  • People who do not wish to provide informed consent
  • People who are considered to be at active risk of suicide

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yvette Sheline, M.D., Center for Neuromodulation in Depression and Stress, University of Pennsylvania

Phone: (215) 746-2637

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 November 2025
Est. completion
21 November 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Montgomery Asberg Depression Rating Scale (MADRS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov